ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Biofrontera Inc

Biofrontera Inc (BFRI)

1.011
-0.019
( -1.84% )
Updated: 13:15:22

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.011
Bid
0.9921
Ask
1.03
Volume
5,179
0.9921 Day's Range 1.0399
0.61 52 Week Range 12.9857
Market Cap
Previous Close
1.03
Open
1.01
Last Trade
1
@
0.9921
Last Trade Time
13:19:51
Financial Volume
$ 5,250
VWAP
1.0136
Average Volume (3m)
80,490
Shares Outstanding
242,353
Dividend Yield
-
PE Ratio
-0.01
Earnings Per Share (EPS)
-83.06
Revenue
34.07M
Net Profit
-20.13M

About Biofrontera Inc

Biofrontera Inc is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, diseases caused by exposure to sunlight that result in sun damage to the skin. Its licensed products focus on the treatment of actinic kerat... Biofrontera Inc is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, diseases caused by exposure to sunlight that result in sun damage to the skin. Its licensed products focus on the treatment of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer. It also markets a topical antibiotic for the treatment of impetigo, a bacterial skin infection. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
1970
Biofrontera Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BFRI. The last closing price for Biofrontera was $1.03. Over the last year, Biofrontera shares have traded in a share price range of $ 0.61 to $ 12.9857.

Biofrontera currently has 242,353 shares outstanding. The market capitalization of Biofrontera is $244,777 . Biofrontera has a price to earnings ratio (PE ratio) of -0.01.

BFRI Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0010.09900990099011.011.10.96179971.04948907CS
4-0.059-5.514018691591.071.15850.87222651.01420577CS
12-0.559-35.60509554141.572.43020.87804901.61203961CS
26-2.379-70.17699115043.393.90.614293371.18856471CS
52-8.769-89.66257668719.7812.98570.612364881.8966357CS
156-80.789-98.764058679781.8292.60.612113388121.25080592CS
260-80.789-98.764058679781.8292.60.612113388121.25080592CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.7151
(137.57%)
294.97M
NXLNexalin Technologies Inc
$ 2.14
(94.55%)
44.32M
SHCRSharecare Inc
$ 1.365
(76.27%)
35.78M
SPECSpectaire Holdings Inc
$ 0.543
(59.71%)
59.4M
MINMMinim Inc
$ 3.83
(33.92%)
42.04M
KAVLKaival Brands Innovations Group Inc
$ 1.475
(-48.61%)
3.35M
FLFVFeutune Light Acquisition Corporation
$ 5.01
(-40.57%)
43.63k
PBMPsyence Biomedical Ltd
$ 0.4039
(-32.68%)
2.28M
RELIReliance Global Group Inc
$ 0.464
(-23.17%)
7.65M
IVDAIveda Solutions Inc
$ 0.451
(-19.82%)
54.16k
NVDANVIDIA Corporation
$ 127.505
(-2.50%)
306.6M
AREBAmerican Rebel Holdings Inc
$ 0.7146
(137.41%)
294.98M
CRKNCrown Electrokinetics Corporation
$ 0.0408
(-18.40%)
139.12M
NKLANikola Corporation
$ 0.3753
(13.87%)
128.36M
ASTIAscent Solar Technologies Inc
$ 0.1114
(3.24%)
114.61M

BFRI Discussion

View Posts
Monksdream Monksdream 3 months ago
BFRI under $2
👍️0
glenn1919 glenn1919 3 months ago
BFRI...............................................https://stockcharts.com/h-sc/ui?s=BFRI&p=W&b=5&g=0&id=p86431144783
👍️0
81vette 81vette 4 months ago
awaiting pop from pp closing,restructure gives new hope,accumulation started fri,shares to short 60k(watching for decline)
👍️0
IoT II IoT II 4 months ago
This is what's really happing in the news:)

https://www.accesswire.com/viewarticle.aspx?id=835060
👍️0
Invest-in-America Invest-in-America 4 months ago
BFRI: Nice trick!!! (WOW, these firms are CLEVER!!!)
👍️0
Awl416 Awl416 4 months ago
That was quick
👍️0
IoT II IoT II 4 months ago
Boom
👍️0
Awl416 Awl416 4 months ago
Form RW - Registration Withdrawal Request
👍️0
IoT II IoT II 4 months ago
We trading baby!!

BFRI$ Bullish
👍️0
Monksdream Monksdream 5 months ago
BFRI new 52 week low
👍️0
Monksdream Monksdream 5 months ago
BFRI new 52 week low
👍️0
Monksdream Monksdream 5 months ago
BFRI new 52=week low
👍️0
Monksdream Monksdream 5 months ago
BFRI new 52 week low
👍️0
Bourne Free Bourne Free 5 months ago
Word on the street is that BFRI is restructuring… laid off a significant number of sales reps today
👍️0
Monksdream Monksdream 5 months ago
BFRI new 52 week low
👍️0
Monksdream Monksdream 6 months ago
BFRI new 52 week low
👍️0
Bourne Free Bourne Free 7 months ago
I would stay away from this stock. If you do your due diligence Biofrontera (AG) & Inc in 25+ years have never turned a profit. Looking at BF AG …5/6 years ago the market cap was over $300 million. Look now at the combined market cap of Inc & AG. It’s a small fraction of that. Further, if you look at the Actinic Keratosis market and the players. The competitor dominates, other modalities are preferable. BF Inc would need $100 million minimum to get to profitability… and even then I don’t think it would. BF has raised about a quarter billion in 25+ years and still can’t turn a profit. It was recently announced that 2 investors bailed. My guess is that you will lose your shirt and everything else with this company. It’s poorly run!
👍️0
Monksdream Monksdream 8 months ago
BFRI new 52 week low
👍️0
Awl416 Awl416 8 months ago
What’s the deal
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
LETS SEE 80C
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
BFRI...BIO BEAST!
👍️0
tw0122 tw0122 1 year ago
Only up 30 to 40% premarket
👍️0
LVerstee LVerstee 1 year ago
Crazy right
👍️0
subslover subslover 1 year ago
$BFRI is up 60% after hours on no news.
👍️0
LVerstee LVerstee 1 year ago
https://www.marketscreener.com/quote/stock/BIOFRONTERA-INC-128192403/news/BIOFRONTERA-INC-Notice-of-Delisting-or-Failure-to-Satisfy-a-Continued-Listing-Rule-or-Standard-T-43135289/
👍️0
sick nam vet sick nam vet 1 year ago
Dead!!!
👍️0
grnindustree grnindustree 1 year ago
So quiet here these days. BFRI
👍️0
StockLogistics StockLogistics 2 years ago
Next chance mid October imo, the 13th
👍️0
StockLogistics StockLogistics 2 years ago
Definitely would want the share price to increase to its appropriate mean level (6.00 imo) to ease the pressure of the 87,000 IRS agents looking into movement of prices and the reasoning thereof, now that it appears the company was bought out getting back to a normal Shareprice could be a financial priority.
👍️0
StockLogistics StockLogistics 2 years ago
BFRI - 2 Friday

The last time a Friday was the 2nd day of the month was July 2, 2021. BFRI opened for trading October 29, 2021.
👍️0
StockLogistics StockLogistics 2 years ago
5 day consolidation completes in 5 minutes
👍️0
StockLogistics StockLogistics 2 years ago
If the share price would rise it would be now if the takeover is completed no need to decrease the price further
👍️0
rocco_p_coletrain rocco_p_coletrain 2 years ago
My guess could be these guys since they already have a nice chuck of this...

Japan's Maruho Co. Ltd. 29.99% stake.
👍️0
StockLogistics StockLogistics 2 years ago
Adding up all the shares from each entity mentioned in the form 13 collectively, since all the entities appear to be interconnected and on the same side of the legal dispute, is still about 37.5 percent of 56 million in my estimation,

The below page lists Zours as current chairman of BFRI:

https://people.equilar.com/bio/wilhelm-zours-biofrontera-ag/33831858

The company could clarify:

Who is in control of the company and by what method was the OS increased.
👍️0
rocco_p_coletrain rocco_p_coletrain 2 years ago
That's based on 25,500,950 o/s.

Now it's 56,717,385 o/s.

They don't own majority anymore.
👍️0
StockLogistics StockLogistics 2 years ago
The chairman of BFRI is also the head of DB, I think the takeover already happened.
👍️0
rocco_p_coletrain rocco_p_coletrain 2 years ago
You're totally right about the increase in the O/S. My guess is that someone what's to take control of the company, other than the guy who's buying up shares currently. Maybe a poison pill is in the works?
👍️0
StockLogistics StockLogistics 2 years ago
The link content is in German I think and I am not going to translate it because I don’t understand how the outstanding shares increased to 56 million, as referenced in the form 13.
👍️0
rocco_p_coletrain rocco_p_coletrain 2 years ago
Have you reviewed the results of the shareholders meeting? Can't post link, but it's on the company website.
👍️0
StockLogistics StockLogistics 2 years ago
Now that the 13-d was filed maybe the SP can be allowed to increase based on the company’s latest numbers which are impressive:

https://www.otcmarkets.com/filing/html?id=16012086&guid=Cl9-kKABeEOCJth
👍️0
StockLogistics StockLogistics 2 years ago
I discovered The cause of the decrease in Shareprice. First, in 2018, Biofrontera claimed in court that the primary goal of major shareholders was to decrease the BFRI Shareprice so that another company, “DB”, could take over Biofrontera:

“Biofrontera files lawsuit against W.K.T. Zours, Deutsche Balaton AG and further defendants
June 12, 2018 08:00 ET
| Source: Biofrontera AG





Leverkusen, Germany, June 12, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that it has filed a complaint in the United States District Court for the Southern District of New York against Wilhelm Konrad Thomas Zours (“Zours”), Deutsche Balaton AG (“Deutsche Balaton”), DELPHI Unternehmensberatung AG, VV Beteiligungen AG, ABC Beteiligungen AG, Deutsche Balaton Biotech AG (“DB Biotech”) (collectively, the “Balaton Defendants”), alleging, among other things, that the Mr. Zours and the other Balaton Defendants have violated federal and state laws in various ways, particularly in connection with DB Biotech’s unsolicited offer to purchase up to 6,250,000 of the Company’s shares in exchange for per-share consideration consisting of one euro plus a warrant entitling the holder thereof to purchase a share of the Company for the price of one euro. The Balaton Defendants together are major shareholders of the Company. Please see Item 7.A—Major Shareholders of the Company’s Annual Report on Form 20-F, filed with the U.S. Securities and Exchange Commission (the “Commission”) on April 30, 2018, for more information on the Balaton Defendants’ holdings of the Company’s shares.

As announced on June 11, 2018, the Company’s management board and supervisory board have published, pursuant to German law, a joint opinion stating their belief that the consideration offered by DB Biotech is insufficient and that successful completion of the tender offer would not be in the interests of the Company and its subsidiaries, its employees or its shareholders, but instead could significantly damage them, and their recommendation that the Company’s shareholders should not accept the offer.

The Company’s complaint against the Defendants alleges, in particular, that:

The Balaton Defendants have violated and continue to violate Section 13(d) of the U.S. Securities Exchange Act of 1934 (the “34 Act”) and the rules thereunder by failing to file a beneficial ownership report on Schedule 13D with the Commission when they were required to do so by U.S. federal securities laws. The Schedule 13D which provides critical information to the Company, its shareholders and other investors or potential investors in the Company relating to the identity, resources and intentions of major shareholders.
The Balaton Defendants have purchased significant amounts of the Company’s shares following public announcement of a tender offer, in violation of the Commission’s Rule 14e-5 under the 34 Act and rules regarding market manipulation, which is a rule designed to prevent fraudulent, deceptive or manipulative acts or practices in connection with a tender offer for equity securities.
By publicly offering warrants in the U.S. as part of its tender offer consideration without filing a registration statement regarding those securities with the Commission, DB Biotech is engaged in an unlawful public offering of securities in the U.S. in violation of Section 5 of the U.S. Securities Act of 1933.
By knowingly or recklessly publishing false and defamatory statements regarding the competency of Biofrontera and its officers and directors and the legality of their actions, Deutsche Balaton and Zours engaged in deceptive and manipulative acts and practices in connection with DB Biotech’s tender offer for the Company’s shares, attempting to depress the Company’s share price in order to make the tender offer more attractive.
Deutsche Balaton and Zours have engaged in libel and trade libel against the Company and its officers and directors by publicly issuing letters containing multiple written defamatory statements concerning Biofrontera which were false and misleading. These letters were available to all on the internet.
Acting out of malice, Deutsche Balaton and Zours tortuously and intentionally interfered with the Company’s initial public offering of American Depositary Shares in the U.S. by publishing false and misleading and defamatory statements on its website while the Company was conducting a U.S. road show and soliciting prospective investors in the U.S.
In addition, the complaint alleges that Axxion S.A. (“Axxion” and, together with the Balaton Defendants, the “Defendants”) has acted in concert with the Balaton Defendants to form a group for the purpose of acquiring and holding the Company’s shares for the purpose or effect of changing or influencing control of the Company, without filing a Schedule 13D as required by U.S. federal securities laws. The Company believes that Axxion and the Balaton Defendants have acted in concert with respect to their holdings of the Company’s shares since February 2016.

These acts are part of a long, concerted and malicious campaign by the Balaton Defendants to embarrass, discredit, distract and injure the Company and its employees, officers, directors and other stakeholders and to control the Company but without acquiring a controlling stake in the Company’s shares. Moreover, the Company’s management believes that the Balaton Defendants have taken these actions—in particular their publication of defamatory and libelous statements about the Company and its management—in order to manipulate and depress the price of the Company’s shares to increase the attractiveness of DB Biotech’s tender offer.

The Company is seeking the following relief (among other remedies):

Compensatory and punitive damages to compensate the Company for injuries suffered as a result of Deutsche Balaton’s and Zours’s libel, trade libel and tortious interference with their business opportunities.
A declaration that the Defendants have violated Section 13(d) of the 34 Act by failing to file with the Commission a beneficial ownership report on Schedule 13D to provide the Company, its shareholders and other investors or potential investors in the Company with critical information that they need in order to make investment decisions.
A declaration that the Balaton Defendants have violated Rule 14e-5.
An injunction mandating the Defendants to file an appropriate Schedule 13D with the Commission and barring them from voting any of their shares, acquiring any shares or otherwise trying to acquire shares of or change or influence control of the Company until six months after such complete and accurate Schedule 13D is filed with the Commission.
An injunction barring the Balaton Defendants from purchasing any additional shares of the Company or voting any shares that they purchased during the tender offer for a period of six months, and certain other relief.”

https://www.globenewswire.com/en/news-release/2018/06/12/1520276/0/en/Biofrontera-files-lawsuit-against-W-K-T-Zours-Deutsche-Balaton-AG-and-further-defendants.html

“Biofrontera AG v. Deutsche Balaton AG (1:18-cv-05237)
District Court, S.D. New York

Date Filed: June 11, 2018
Date Terminated: Dec. 20, 2021
Date of Last Known Filing: Dec. 20, 2021”

https://www.courtlistener.com/docket/7122004/biofrontera-ag-v-deutsche-balaton-ag/

On august 5, The Biofrontera employees accused the supervisory board of neglect towards them and of inefficient management:

https://www.biofrontera.com/fileadmin/files/PDFs/Takeover_offer_DB/20220808_Stellungnahme_AR_zur_Stellungnahme_der_Mitarbeiter_final.pdf

“TAKEOVER OFFER DEUTSCHE BALATON AG

Deutsche Balaton AG with its registered office in Heidelberg ("Bidder") announced its decision to make a voluntary public takeover offer for all shares in Biofrontera AG ("Offer") on 07 June 2022. It published the offer document on July 15, 2022. Publications by the Bidder regarding the Offer can be found at www.deutsche-balaton.de/beteiligungen/uebernahmeangebot-biofrontera/. Biofrontera AG does not assume any responsibility for the publications of the Bidder and does not adopt them as its own.

The Management Board and the Supervisory Board of Biofrontera AG are obliged to issue a reasoned statement on the Offer and on each of its amendments pursuant to section 27 WpÜG.

These statement(s) can be found below:

Statement of the Management Board and Supervisory Board on the atake over offer of Deutsche Balaton AG pursuant to section 27 WpÜG - 29.07.2022 (PDF)
Statement by employees on the acquisition offer of Deutsche Balaton AG pursuant to section 27 WpÜG - August 02, 2022 (PDF)
Statement of the Supervisory Board on the statement of the employees on the acquisition offer of Deutsche Balaton AG pursuant to Sec. 27 (2) WpÜG - August 08,2022 (PDF, German only)“

https://www.biofrontera.com/en/investors/takeover-offer-of-deutsche-balaton-ag

One of the defendants in the case disclosed a 37.5% stake in the company on Thursday:


“SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. )*

Biofrontera Inc.
(Name of Issuer)

Common Stock, par value $0.001 per share
(Title of Class of Securities)

09077D 100
(CUSIP Number)

Rolf Birkert
Member of the Board
Deutsche Balaton Aktiengesellschaft
Ziegelhaeuser Landstrasse 1
69120 Heidelberg
Germany”

“Person Instrument Transaction Date
Quantity Purchased/
(Sold)
Price per Instrument(1) Place of Transaction

DB Biofrontera Inc. common stock August 15, 2022 25,000 EUR1.305 BVT Brokernetzwerk

DB Biofrontera Inc. common stock August 15, 2022 25,000 EUR1.324 BVT Brokernetzwerk

DB Biofrontera Inc. common stock August 15, 2022 25,000 EUR1.334 BVT Brokernetzwerk

DB Biofrontera Inc. common stock August 15, 2022 25,000 EUR1.343 BVT Brokernetzwerk

DB Biofrontera Inc. common stock August 16, 2022 25,000 EUR1.182 BVT Brokernetzwerk

DB Biofrontera Inc. common stock August 16, 2022 25,000 EUR1.182 BVT Brokernetzwerk

DB Biofrontera Inc. common stock August 16, 2022 10,000 EUR1.184 BVT Brokernetzwerk

DB Biofrontera Inc. common stock August 16, 2022 25,000 EUR1.145 BVT Brokernetzwerk

DB Biofrontera Inc. common stock August 17, 2022 25,000 EUR1.153 BVT Brokernetzwerk

DB Biofrontera Inc. common stock August 17, 2022 25,000 EUR1.160 BVT Brokernetzwerk

DB Biofrontera Inc. common stock August 17, 2022 25,000 EUR1.161 BVT Brokernetzwerk

DB Biofrontera Inc. common stock August 17, 2022 25,000 EUR1.154 BVT Brokernetzwerk

DB Biofrontera Inc. common stock August 17, 2022 25,000 EUR1.161 BVT Brokernetzwerk

DB Biofrontera Inc. common stock August 17, 2022 25,000 EUR1.161 BVT Brokernetzwerk

DB Biofrontera Inc. common stock August 17, 2022 21,767 EUR1.119 BVT Brokernetzwerk

DB Biofrontera Inc. common stock August 23, 2022 3,967 USD1.109644 BVT Brokernetzwerk

DB Biofrontera Inc. common stock August 23, 2022 25,000 USD1.12 BVT Brokernetzwerk

“ Based on 56,717,385 shares of Biofrontera AG outstanding as of August 23, 2022. Deutsche Balaton Biotech AG (“DBB”) owns 2,280,847 shares in Biofrontera AG; SPARTA AG (“SP”) owns 4,084,941 shares of Biofrontera AG; Heidelberger Beteiligungsholding AG (“HDBH”) owns 1,200 shares of Biofrontera AG; DB owns 2,630,661 shares of Biofrontera AG; and DU owns 8,350,030 shares of Biofrontera AG. DB owns a majority interest in each of DBB, SP and HDBH. In addition, each of DBB, SP, HDBH, DB and DU entered into an acting-in-concert agreement, pursuant to which each such party agrees to exercise their voting rights in Biofrontera AG (or abstain therefrom) in accordance with the terms thereof.

11


All percentages relating to the Common Stock set forth in this Schedule 13D are based upon 23,550,960 shares outstanding as reported in the Issuer’s Form 10-Q filed on August 12, 2022 and calculated in accordance with Rule 13d-3 under the Exchange Act of 1934, as amended.”


https://www.sec.gov/Archives/edgar/data/1858685/000121390022051105/ea164873-13ddeutsc_bio.htm

Even with all the buying above the price has decreased because this OTC information on O/S is not close to accurate:

“Share Structure

Market Cap Market Cap
21,038,841
08/26/2022
Authorized Shares
Not Available
Outstanding Shares
17,104,749
04/07/2022
Restricted
Not Available
Unrestricted
Not Available
Held at DTC
Not Available
Float
Not Available
Par Value
Not Available“

https://www.otcmarkets.com/stock/BFRI/security

The O/S more than doubled last month to 56 million O/S as per the above 13-D, and thus has more than tripled this year, hence the downturn in Shareprice.
👍️0
Alice-N-Wonderland Alice-N-Wonderland 2 years ago
Took a loss here. Sold at $1.67 Median price target of $15+ Will try and get back in if i can catch part of a positive wave. They are suppose to give an update soon on when they will release earnings. Good Luck!
👍️0
masterofdisaster masterofdisaster 2 years ago
Well today's news sucked
👍️0
masterofdisaster masterofdisaster 2 years ago
BFRI is back in play
👍️0
da_stock_analyst da_stock_analyst 2 years ago
#BFRI ?? Big move coming this week? Buyout happening? Bullish chart and ready for run! price targets
👍️0
grnindustree grnindustree 2 years ago
Scooped up some during the day on Friday before things heated up later. Any particular reason for the high volume and price bump? Glad to get in when I did (-:

GRN
👍️0
Alice-N-Wonderland Alice-N-Wonderland 2 years ago
Bought in during AH. 560 shares @2.03

GLTA
👍️0
StockLogistics StockLogistics 2 years ago
“3:44p ET 4/13/2022 - Benzinga
Why Biofrontera Stock Is Surging Today

Biofrontera Inc (NASDAQ: BFRI) shares are trading significantly higher Wednesday after the company announced it received U.S. Food and Drug Administration approval for its cGMP laboratory in Germany.

The FDA has approved Biofrontera's German laboratory as a contract lab for batch control and stability testing of Ameluz. This recognition enables significant improvements in product manufacturing efficiency, quality control and reliability of supply.

The clearance will allow part of the necessary testing of production batches to be performed in the company's Germany-based facility, thereby reducing dependence on third-party suppliers and the risk of production downtime and product delays.

Biofrontera is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions.

BFRI 52-Week Range: $2.20 - $14.63

According to data from Benzinga Pro, the stock was up 42.3% at $5.27 at time of publication.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”

Since 4/13 - has closed six times below the lower bollinger band on the 3 month chart without closing above the upper bollinger band, earnings yoy expected up 30%, 10 million shares traded the last 5 days, is Armistice capital done selling ? The chart is overdue for a major increase, let’s have some sort of product communication before open that energizes this shareprice. 18.95 million O/S, would be a missed chart opportunity imo if nothing is promoted. BFRI was at 5.27 a share based on that news, so factoring in interest rate increases as priced in already why is this stock at an all time low, nothing else changed other than reporting the best first half revenue ever recorded. BFRI is 75% less valuable today than 3 months ago based on what metric.
👍️0
StockLogistics StockLogistics 2 years ago
“8:00a ET 7/12/2022 - Globe Newswire
Biofrontera Inc. Announces Preliminary Product Revenues for the Second Quarter of 2022

EQNX::TICKER_START (NASDAQ:BFRI ),(NASDAQ:BFRIW), EQNX::TICKER_END Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today preliminary unaudited product revenues for the six and three months ended June 30, 2022.

For the first half of 2022, product revenues are anticipated to be in the range of approximately $14.1 million to $14.3 million, representing an increase of approximately 34% to 36% compared with the first half of 2021. This represents the strongest first six-month revenues of a year Biofrontera ever had, 102-105% higher than in 2020 and 22-24% higher than the pre-Covid year 2019.

As anticipated because of the effect of a price increase, product revenues for the second quarter of 2022 are expected to be in the range of approximately $4.4 million to $4.6 million, representing a decrease of approximately 21% to 25% compared with the second quarter of 2021.

"I'm proud of the performance by our sales team as we continue to expand awareness of Ameluz, achieve deeper penetration among current customer accounts and drive sales for the brand. Second quarter product revenues reflect the April 1, 2022 price increase that resulted in some advance purchases of Ameluz in the first quarter," commented Erica Monaco, Chief Executive Officer of Biofrontera Inc. "Despite the expected year-over-year quarterly decline, year-to-date product revenues increased. We continue to execute toward upcoming clinical milestones and remain on track with previously-announced financial guidance for 2022 total revenues to increase by at least 30% compared with 2021, including typical seasonal strength in the first and fourth quarters."

The preliminary unaudited product revenues described in this press release are estimates only and are based on currently available information. Final results may vary from the preliminary product revenues estimates. Biofrontera expects to report financial results for the second quarter of 2022 in August 2022. Details concerning that announcement and conference call will be provided in the coming weeks.”
👍️0
StockLogistics StockLogistics 2 years ago
B Fri up up and away like the bird
👍️0

Your Recent History

Delayed Upgrade Clock